Literature DB >> 16357839

Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice.

L Hambach, B A Nijmeijer, Z Aghai, M L J van Schie, M H M Wauben, J H F Falkenburg, E Goulmy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16357839     DOI： 10.1038/sj.leu.2404056

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

Review 2.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.

Authors:  Jeffrey S Miller; Edus H Warren; Marcel R M van den Brink; Jerome Ritz; Warren D Shlomchik; William J Murphy; A John Barrett; Hans Jochem Kolb; Sergio Giralt; Michael R Bishop; Bruce R Blazar; J H Frederik Falkenburg
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-10       Impact factor: 5.742

Review 4.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

5.  Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.

Authors:  Sarah Nicholls; Karen P Piper; Fiyaz Mohammed; Timothy R Dafforn; Stefan Tenzer; Mahboob Salim; Premini Mahendra; Charles Craddock; Peter van Endert; Hansjörg Schild; Mark Cobbold; Victor H Engelhard; Paul A H Moss; Benjamin E Willcox
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 6.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

7.  Naturally acquired tolerance and sensitization to minor histocompatibility antigens in healthy family members.

Authors:  Astrid G S van Halteren; Ewa Jankowska-Gan; Antoinette Joosten; Els Blokland; Jos Pool; Anneke Brand; William J Burlingham; Els Goulmy
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

8.  Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.

Authors:  R Oostvogels; M C Minnema; M van Elk; R M Spaapen; G D te Raa; B Giovannone; A Buijs; D van Baarle; A P Kater; M Griffioen; E Spierings; H M Lokhorst; T Mutis
Journal:  Leukemia       Date:  2012-10-01       Impact factor: 11.528

9.  The human minor histocompatibility antigen 1 is a RhoGAP.

Authors:  Bart-Jan de Kreuk; Antje Schaefer; Eloise C Anthony; Simon Tol; Mar Fernandez-Borja; Dirk Geerts; Jos Pool; Lothar Hambach; Els Goulmy; Peter L Hordijk
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.

Authors:  Ezogelin Oflazoglu; Mark Elliott; Hiroshi Takita; Soldano Ferrone; Robert A Henderson; Elizabeth A Repasky
Journal:  J Transl Med       Date:  2007-06-25       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.